MedTrace Logo

The Prevention of Erythropoietin on Cardiac Surgery-associated Acute Kidney Injury

NCT03007537 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2023-01-26

Study results available
· View outcomes & findings →

Summary

To testify the prevention of Erythropoietin on cardiac surgery associated-acute kidney injury, and trying to provide evidence for protecting the renal function and improving the prognosis for patients after cardiac surgery.

Conditions

Interventions

DRUG

Erythropoietin

10000 IU erythropoietin, subcutaneous injection

DRUG

0.9% sodium chloride

0.9% sodium chloride 1ml, subcutaneous injection

PROCEDURE

cardiac surgery

included valve, coronary artery bypass graft or surgery for congenital heart diseases

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Principal Investigators

  • Xin Chen, Doctor · Nanjing First Hospital, Nanjing Medical University

  • Xin Wan, Doctor · Nanjing First Hospital, Nanjing Medical University

  • Changchun Cao, Doctor · Nanjing First Hospital, Nanjing Medical University

  • Xin Du, Doctor · Nanjing First Hospital, Nanjing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2018-12-28
Completion
2018-12-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03007537 on ClinicalTrials.gov